FDA draft guidelines for the clinical evaluation of antiinflammatory and antirheumatic drugs in children. Executive summary.
Giannini
E H
EH
Children's Hospital Medical Center, University of Cincinnati College of Medicine, Ohio, USA.
Lovell
D J
DJ
Hepburn
B
B
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003257:Consumer Product Safety; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents